ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Egetis Therapeutics AB (publ) (EGTX.ST)
Egetis Therapeutics AB (publ) stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Nasdaq Stockholm · Sweden
SEK 9.77▲ +5.62%
Prices as of Oct 27, 2026 · SEK
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Egetis Therapeutics AB (publ) in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Egetis Therapeutics AB (publ)
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Egetis Therapeutics AB (publ) a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between SEK 8.83 and SEK 10.66; in 9 out of 10, between SEK 7.48 and SEK 12.60. Estimated annual volatility is 51%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- SEK 4.3B
- Market cap (USD)
- $437M
- 52-week high
- SEK 10.14
- 52-week low
- SEK 3.63
- Revenue (12 months)
- SEK 66.0M
- Gross margin
- 16.7%
- Net margin
- 0.0%
- Beta
- 0.78
What this means
ATLAS does not publish a fair value for EGTX.ST right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks EGTX.ST has traded between SEK 3.63 and SEK 10.14. Today it is 3.7% below that high and 170% above its low.
Its beta is 0.78: it tends to move less than the market.
About the company
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
Want to see everything about Egetis Therapeutics AB (publ)?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Egetis Therapeutics AB (publ) do?
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally.
What is the chance EGTX.ST goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, EGTX.ST ends the month between SEK 8.83 and SEK 10.66.
How big is Egetis Therapeutics AB (publ) and what is its P/E ratio?
Egetis Therapeutics AB (publ)'s market capitalization is SEK 4.3B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is EGTX.ST?
ATLAS estimates annual volatility at 51%. In a typical month, half of the outcomes end between SEK 8.83 and SEK 10.66.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer